RECRUITING

Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

Talk to us

Conditions

Hip Osteoarthritisplatelet rich plasmaPRPhip OACorticosteroids

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Official Title

The Efficacy of Platelet Rich Plasma Compared with Corticosteroid Injections for the Treatment of Pain Associated with Hip Osteoarthritis

Quick Facts

Study Start:2024-02-21
Study Completion:2025-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06793982

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Provision of signed and dated informed consent form
  2. * Stated willingness to comply with all study procedures and availability for the duration of the study
  3. * Male or female, aged 21-80 years
  4. * Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis
  5. * Indicated for a Hip injection to treat Hip OA symptoms
  1. * Any injections into the target Hip within three months
  2. * Current overlying skin infection
  3. * Current or previous diagnosis of "chronic pain"
  4. * Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)
  5. * Allergy to any potential ingredients or medications utilized in any of the two groups
  6. * Treatment with another investigational drug or other intervention for pain
  7. * Diagnosis of Diabetes Mellitus
  8. * If female, pregnant or planning to be pregnant within the following 3 months or study duration
  9. * Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation

Contacts and Locations

Study Contact

Martin Gesheff, DHSc
CONTACT
410-601-9467
mgesheff@lifebridgehealth.org

Study Locations (Sites)

Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
United States

Collaborators and Investigators

Sponsor: LifeBridge Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-21
Study Completion Date2025-12-01

Study Record Updates

Study Start Date2024-02-21
Study Completion Date2025-12-01

Terms related to this study

Keywords Provided by Researchers

  • platelet rich plasma
  • hip osteoarthritis
  • PRP
  • hip OA
  • Corticosteroids

Additional Relevant MeSH Terms

  • Hip Osteoarthritis